Patent ID: 7977306

Claim:
A method of treating diabetes in a patient, comprising administering an albumin fusion protein comprising two or more tandemly oriented GLP-1 polypeptides, wherein (i) said GLP-1 polypeptides are selected from wild-type GLP-1, GLP -1 fragments, and GLP-1 variants, fused to albumin comprising the amino acid sequence of SEQ ID NO:327, an albumin fragment, or albumin variant thereof, (ii) said albumin fragment or albumin variant increases the serum plasma half-life of the GLP-1 polypeptides, (iii) said fusion protein has GLP-1 activity, and (iv) wherein said patient is also suffering from a condition selected from the group consisting of: (a) neural disorder; (b) neuropathy; (c) retinopathy; (d) cardiovascular disorder; (e) renal disorder; and (f) obesity.